z-logo
Premium
Botulinum toxin type A injection for refractory interstitial cystitis: A randomized comparative study and predictors of treatment response
Author(s) -
Akiyama Yoshiyuki,
Nomiya Akira,
Niimi Aya,
Yamada Yukio,
Fujimura Tetsuya,
Nakagawa Tohru,
Fukuhara Hiroshi,
Kume Haruki,
Igawa Yasuhiko,
Homma Yukio
Publication year - 2015
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/iju.12833
Subject(s) - medicine , refractory (planetary science) , interstitial cystitis , botulinum toxin , prospective cohort study , group b , cohort , randomized controlled trial , surgery , anesthesia , urinary system , physics , astrobiology
Objectives To determine whether botulinum toxin type A can represent an alternative treatment option for patients with interstitial cystitis refractory to conventional therapies. Methods This is a single‐center, prospective, open labeled, randomized comparative study. Patients with refractory interstitial cystitis were randomly divided into two groups: immediate injection (group A) or 1‐month delayed injection (group B) of botulinum toxin type A after allocation. The rate of treatment response (global response assessment ≥+1: slightly improved), and changes in symptom scores and frequency volume chart variables were compared between groups 1 month after allocation. Using subjects of both groups as a single cohort, predictive factors for treatment response at 1 month post‐injection and the duration of response were explored. Results A total of 34 patients (group A n  = 18, group B n  = 16) were allocated. The response rate was significantly higher in group A than group B (72.2% vs 25.0%, P  = 0.01). All symptom measures showed significant improvement in group A than group B. When both groups were combined as a single cohort, the response rate was 73.5% at 1 month, 58.8% at 3 months, 38.2% at 6 months and 20.6% at 12 months. The mean duration of response was 5.4 months. Multivariate analysis showed that past exposure to hydrodistension more than three times correlated with better outcomes. Conclusions Botulinum toxin type A injection could be an alternative treatment option for patients with interstitial cystitis refractory to conventional therapies, especially for those who have received repeated hydrodistensions and transurethral fulguration.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here